Literature DB >> 29549387

One-stage exchange with antibacterial hydrogel coated implants provides similar results to two-stage revision, without the coating, for the treatment of peri-prosthetic infection.

Nicola Capuano1, Nicola Logoluso2, Enrico Gallazzi2, Lorenzo Drago3, Carlo Luca Romanò4.   

Abstract

PURPOSE: Aim of this study was to verify the hypothesis that a one-stage exchange procedure, performed with an antibiotic-loaded, fast-resorbable hydrogel coating, provides similar infection recurrence rate than a two-stage procedure without the coating, in patients affected by peri-prosthetic joint infection (PJI).
METHODS: In this two-center case-control, study, 22 patients, treated with a one-stage procedure, using implants coated with an antibiotic-loaded hydrogel [defensive antibacterial coating (DAC)], were compared with 22 retrospective matched controls, treated with a two-stage revision procedure, without the coating.
RESULTS: At a mean follow-up of 29.3 ± 5.0 months, two patients (9.1%) in the DAC group showed an infection recurrence, compared to three patients (13.6%) in the two-stage group. Clinical scores were similar between groups, while average hospital stay and antibiotic treatment duration were significantly reduced after one-stage, compared to two-stage (18.9 ± 2.9 versus 35.8 ± 3.4 and 23.5 ± 3.3 versus 53.7 ± 5.6 days, respectively).
CONCLUSIONS: Although in a relatively limited series of patients, our data shows similar infection recurrence rate after one-stage exchange with DAC-coated implants, compared to two-stage revision without coating, with reduced overall hospitalization time and antibiotic treatment duration. These findings warrant further studies in the possible applications of antibacterial coating technologies to treat implant-related infections. LEVEL OF EVIDENCE: III.

Entities:  

Keywords:  Coating; DAC; Infection; One-stage revision; PJI; Two-stage revision

Mesh:

Substances:

Year:  2018        PMID: 29549387     DOI: 10.1007/s00167-018-4896-4

Source DB:  PubMed          Journal:  Knee Surg Sports Traumatol Arthrosc        ISSN: 0942-2056            Impact factor:   4.342


  49 in total

1.  Infected total hip arthroplasty revision: one- or two-stage procedure?

Authors:  S Klouche; P Leonard; V Zeller; L Lhotellier; W Graff; P Leclerc; P Mamoudy; E Sariali
Journal:  Orthop Traumatol Surg Res       Date:  2012-02-24       Impact factor: 2.256

2.  Comparison of one-stage revision with antibiotic cement versus two-stage revision results for infected total hip arthroplasty.

Authors:  Ho-Rim Choi; Young-Min Kwon; Andrew A Freiberg; Henrik Malchau
Journal:  J Arthroplasty       Date:  2013-08-20       Impact factor: 4.757

3.  Prosthetic joint infection following total hip replacement: results of one-stage versus two-stage exchange.

Authors:  Matthias Wolf; Heimo Clar; Jörg Friesenbichler; Gerold Schwantzer; Gerwin Bernhardt; Gerald Gruber; Mathias Glehr; Andreas Leithner; Patrick Sadoghi
Journal:  Int Orthop       Date:  2014-03-18       Impact factor: 3.075

Review 4.  One-stage versus two-stage exchange arthroplasty for infected total knee arthroplasty: a systematic review.

Authors:  Navraj S Nagra; Thomas W Hamilton; Sameer Ganatra; David W Murray; Hemant Pandit
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-09-21       Impact factor: 4.342

Review 5.  Biomaterials approaches to treating implant-associated osteomyelitis.

Authors:  Jason A Inzana; Edward M Schwarz; Stephen L Kates; Hani A Awad
Journal:  Biomaterials       Date:  2015-12-18       Impact factor: 12.479

Review 6.  Periprosthetic joint infection.

Authors:  Bhaveen H Kapadia; Richard A Berg; Jacqueline A Daley; Jan Fritz; Anil Bhave; Michael A Mont
Journal:  Lancet       Date:  2015-06-28       Impact factor: 79.321

7.  Cementless revision for infected hip arthroplasty: an 8.6 years follow-up.

Authors:  Peng Li; Ming Hou; Zhi-Qi Zhu; Zhan-Jun Shi
Journal:  Orthop Surg       Date:  2015-02       Impact factor: 2.071

8.  Comparison of one and two-stage revision of total hip arthroplasty complicated by infection: a Markov expected-utility decision analysis.

Authors:  Christopher F Wolf; Ning Yan Gu; Jason N Doctor; Paul A Manner; Seth S Leopold
Journal:  J Bone Joint Surg Am       Date:  2011-04-06       Impact factor: 5.284

9.  Total hip arthroplasties: what are the reasons for revision?

Authors:  Slif D Ulrich; Thorsten M Seyler; Derek Bennett; Ronald E Delanois; Khaled J Saleh; Issada Thongtrangan; Michael Kuskowski; Edward Y Cheng; Peter F Sharkey; Javad Parvizi; James B Stiehl; Michael A Mont
Journal:  Int Orthop       Date:  2007-04-19       Impact factor: 3.075

10.  Fast-resorbable antibiotic-loaded hydrogel coating to reduce post-surgical infection after internal osteosynthesis: a multicenter randomized controlled trial.

Authors:  Kostantinos Malizos; Michael Blauth; Adrian Danita; Nicola Capuano; Riccardo Mezzoprete; Nicola Logoluso; Lorenzo Drago; Carlo Luca Romanò
Journal:  J Orthop Traumatol       Date:  2017-02-02
View more
  4 in total

1.  Periprosthetic Knee Infection - Part 2: Treatment.

Authors:  João Maurício Barretto; André Luiz Siqueira Campos; Nelson Hiroyuki Miyabe Ooka
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2022-05-27

2.  Antibacterial hydrogel coating in joint mega-prosthesis: results of a comparative series.

Authors:  Carmine Zoccali; Guido Scoccianti; Roberto Biagini; Primo Andrea Daolio; Fabio Luca Giardina; Domenico Andrea Campanacci
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-02-05

3.  Antibiotic-Loaded Hydrogel Coating to Reduce Early Postsurgical Infections in Aseptic Hip Revision Surgery: A Retrospective, Matched Case-Control Study.

Authors:  Daniele De Meo; Valeria Calogero; Lorenzo Are; Armando U Cavallo; Pietro Persiani; Ciro Villani
Journal:  Microorganisms       Date:  2020-04-15

4.  Megaprostheses for the revision of infected hip arthroplasties with severe bone loss.

Authors:  Nicola Logoluso; Francesca Alice Pedrini; Carlo Luca Romanò; Antonio Virgilio Pellegrini; Ilaria Morelli; Elena De Vecchi
Journal:  BMC Surg       Date:  2022-02-25       Impact factor: 2.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.